NO972529L - Forbindelse for inhibering av mavesyresekresjon - Google Patents

Forbindelse for inhibering av mavesyresekresjon

Info

Publication number: NO972529L
Authority: NO; Norway
Prior art keywords: salt; treatment; compound; intended; quinoline
Prior art date: 1994-12-08

Application number

NO972529A

Other languages

English (en)

Norwegian (no)

Other versions

NO972529D0 (no

Inventor

Ingemar Starke

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-08

Filing date

1997-06-03

Publication date

1997-06-03

1997-06-03 Application filed by Astra Ab filed Critical Astra Ab

1997-06-03 Publication of NO972529L publication Critical patent/NO972529L/no

1997-06-03 Publication of NO972529D0 publication Critical patent/NO972529D0/no

Links

150000001875 compounds Chemical class 0.000 title claims description 26
230000005764 inhibitory process Effects 0.000 title claims description 13
230000009858 acid secretion Effects 0.000 title description 6
210000002784 stomach Anatomy 0.000 title description 5
150000003839 salts Chemical class 0.000 claims description 50
238000011282 treatment Methods 0.000 claims description 24
230000027119 gastric acid secretion Effects 0.000 claims description 16
XNTVAQRDRZKWDH-UHFFFAOYSA-N 1-[4-(2-methylanilino)-8-(2-methylsulfinylethoxy)quinolin-3-yl]butan-1-one Chemical compound CCCC(=O)C1=CN=C2C(OCCS(C)=O)=CC=CC2=C1NC1=CC=CC=C1C XNTVAQRDRZKWDH-UHFFFAOYSA-N 0.000 claims description 13
208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 13
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 13
239000004480 active ingredient Substances 0.000 claims description 12
150000003892 tartrate salts Chemical class 0.000 claims description 12
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 11
210000001156 gastric mucosa Anatomy 0.000 claims description 10
230000002401 inhibitory effect Effects 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
238000011321 prophylaxis Methods 0.000 claims description 9
241000590002 Helicobacter pylori Species 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
229940037467 helicobacter pylori Drugs 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
239000004599 antimicrobial Substances 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 4
230000000845 anti-microbial effect Effects 0.000 claims 2
206010019375 Helicobacter infections Diseases 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
238000012360 testing method Methods 0.000 description 16
239000002253 acid Substances 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 9
230000002496 gastric effect Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000003248 secreting effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
210000004051 gastric juice Anatomy 0.000 description 3
238000001802 infusion Methods 0.000 description 3
-1 quinoline compound Chemical class 0.000 description 3
238000001665 trituration Methods 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
201000000052 gastrinoma Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
ICRDWGZYVURRLS-UHFFFAOYSA-N 1-[4-(2-methylanilino)-8-(2-methylsulfanylethoxy)quinolin-3-yl]butan-1-one Chemical compound CCCC(=O)C1=CN=C2C(OCCSC)=CC=CC2=C1NC1=CC=CC=C1C ICRDWGZYVURRLS-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
241000272470 Circus Species 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
239000001358 L(+)-tartaric acid Substances 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010079943 Pentagastrin Proteins 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
150000001621 bismuth Chemical class 0.000 description 1
MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
229940036358 bismuth subcarbonate Drugs 0.000 description 1
229960004645 bismuth subcitrate Drugs 0.000 description 1
JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
229960000199 bismuth subgallate Drugs 0.000 description 1
229960001482 bismuth subnitrate Drugs 0.000 description 1
ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
229960000782 bismuth subsalicylate Drugs 0.000 description 1
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 1
230000037396 body weight Effects 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
229960005361 cefaclor Drugs 0.000 description 1
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
229960002129 cefixime Drugs 0.000 description 1
OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
229960002549 enoxacin Drugs 0.000 description 1
IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229960004931 histamine dihydrochloride Drugs 0.000 description 1
PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
229960000444 pentagastrin Drugs 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000036269 ulceration Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO972529A 1994-12-08 1997-06-03 Forbindelse for inhibering av mavesyresekresjon NO972529D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/351,852 US5556863A (en)	1993-06-11	1994-12-08	Compound for gastric acid secretion inhibition
PCT/SE1995/001369 WO1996017830A1 (en)	1994-12-08	1995-11-17	Compounds for inhibition of gastric acid secretion

Publications (2)

Publication Number	Publication Date
NO972529L true NO972529L (no)	1997-06-03
NO972529D0 NO972529D0 (no)	1997-06-03

Family

ID=23382690

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO972529A NO972529D0 (no)	1994-12-08	1997-06-03	Forbindelse for inhibering av mavesyresekresjon

Country Status (20)

Country	Link
US (1)	US5556863A (pt)
EP (1)	EP0796249A1 (pt)
JP (1)	JPH10510259A (pt)
CN (1)	CN1169142A (pt)
AR (1)	AR001996A1 (pt)
BR (1)	BR9509888A (pt)
CA (1)	CA2205896A1 (pt)
EE (1)	EE9700131A (pt)
FI (1)	FI972410A0 (pt)
HU (1)	HUT77949A (pt)
IL (1)	IL116285A0 (pt)
IS (1)	IS4485A (pt)
MX (1)	MX9704136A (pt)
NO (1)	NO972529D0 (pt)
NZ (1)	NZ297566A (pt)
PL (1)	PL320754A1 (pt)
SK (1)	SK63797A3 (pt)
TR (1)	TR199501536A2 (pt)
WO (1)	WO1996017830A1 (pt)
ZA (1)	ZA9510066B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA80393C2 (uk)	2000-12-07	2007-09-25	Алтана Фарма Аг	Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4042702A (en) *	1973-08-16	1977-08-16	Byk Gulden Lomberg Chemische Fabrik Gmbh	Halogen pyrazole derivatives, a method for producing these halogen pyrazole derivatives, medicaments containing and methods of using them
LU69428A1 (pt) *	1974-02-20	1975-12-09
US4120972A (en) *	1975-02-03	1978-10-17	Smith Kline & French Laboratories Limited	Imidazolylmethylthio-ethyl isothiourea compounds
ATA210876A (de) *	1975-03-25	1979-01-15	Byk Gulden Lomberg Chem Fab	Verfahren zur herstellung von neuen nidrofuryl- pyrazolderivaten
AT364354B (de) *	1976-10-14	1981-10-12	Byk Gulden Lomberg Chem Fab	Verfahren zur herstellung von neuen pyrazol-1yl-phenylessigsaeuren, deren salzen und optischen isomeren
LU78804A1 (de) *	1977-12-30	1979-07-20	Byk Gulden Lomberg Chem Fab	N-substituierte w-aminoalkanoyl-w-aminoalkansaeuren,ihre verwendung und verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US4243678A (en) *	1977-12-30	1981-01-06	Byk Gulden Lomberg Chemische Fabrik Gmbh	Acylhydrocarbylaminoalkanoic acids, compositions and uses
YU118379A (en) *	1978-05-24	1983-02-28	Byk Gulden Lomberg Chemischefa	Process for preparing phenylaminothiophene acetic acid
US4343804A (en) *	1979-03-26	1982-08-10	A. H. Robins Company, Inc.	4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
EP0064775A1 (de) *	1979-08-03	1982-11-17	Byk Gulden Lomberg Chemische Fabrik GmbH	Substituierte Tetraazatricyclen, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0024638A1 (en) *	1979-08-30	1981-03-11	Byk Gulden Lomberg Chemische Fabrik GmbH	Substituted quinolinone-alkanecarboxylic acids, their preparation, and medicaments containing them
EP0025192B1 (de) *	1979-09-07	1983-05-11	Byk Gulden Lomberg Chemische Fabrik GmbH	Substituierte Oxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel
ES8202780A1 (es) *	1979-10-31	1982-03-01	Byk Gulden Lomberg Chem Fab	Procedimiento para la preparacion de acidos oxocarboxilicos sustituidos
US4381301A (en) *	1980-05-07	1983-04-26	Byk Gulden Lomberg Chemische Fabrik Gmbh	Substituted tricyclic thieno compounds, their synthesis, their use, their compositions and their medicaments
US4337267A (en) *	1980-08-25	1982-06-29	Byk Gulden Lomberg Chemische Fabrik Gmbh	Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, their use and medicaments containing them
WO1982000822A1 (en) *	1980-08-29	1982-03-18	Eistetter K	Substituted oxiranecarboxylic acids,their preparation and their use as medicaments
EP0057428B1 (de) *	1981-02-02	1985-04-10	Byk Gulden Lomberg Chemische Fabrik GmbH	Tricyclische Pyrrole, Verfahren zu ihrer Herstellung, ihre Anwendung sowie sie enthaltende Arzneimittel
FI80022C (fi) *	1982-07-05	1990-04-10	Otsuka Pharma Co Ltd	Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat.
DK585485A (da) *	1984-12-18	1986-08-08	Utsuka Pharm Co Ltd	Tetrahydroquinolinderivat, imidazopyridinderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat med mindst en saadan forbindelse
US5250527A (en) *	1985-10-24	1993-10-05	Smithkline & French Laboratories Limited	Pyridyl containing benzimidazoles, compositions and use
GB8621425D0 (en) *	1986-09-05	1986-10-15	Smith Kline French Lab	Compounds
GB8717644D0 (en) *	1987-07-24	1987-09-03	Smithkline Beckman Intercredit	Compounds
GB8804445D0 (en) *	1988-02-25	1988-03-23	Smithkline Beckman Intercredit	Compounds
GB8804443D0 (en) *	1988-02-25	1988-03-23	Smithkline Beckman Intercredit	Compounds
GB8804446D0 (en) *	1988-02-25	1988-03-23	Smithkline Beckman Intercredit	Compounds
GB8804447D0 (en) *	1988-02-25	1988-03-23	Smithkline Beckman Intercredit	Compounds
GB8804448D0 (en) *	1988-02-25	1988-03-23	Smithkline Beckman Intercredit	Compounds
GB8804444D0 (en) *	1988-02-25	1988-03-23	Smithkline Beckman Intercredit	Compounds
US5049567A (en) *	1988-02-25	1991-09-17	Smithkline Beckman Intercredit B.V.	Substituted 4-aminoquinazoline derivatives and method of use
CA2011086A1 (en) *	1989-03-17	1990-09-17	Karl-Heinz Geiss	2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) *	1989-04-12	1989-05-24	Smithkline Beckman Intercredit	Compounds
GB8910722D0 (en) *	1989-05-10	1989-06-28	Smithkline Beckman Intercredit	Compounds
DE3917233A1 (de) *	1989-05-26	1990-11-29	Basf Ag	8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
GB8918265D0 (en) *	1989-08-10	1989-09-20	Smithkline Beckman Intercredit	Compounds
DK0480052T3 (da) *	1990-03-28	1998-05-11	Otsuka Pharma Co Ltd	Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet
EP0569396A1 (en) *	1991-01-29	1993-11-18	Smithkline Beecham Intercredit B.V.	Salts of a 4-amino-3-acyl quinoline derivative and their use as inhibitors of gastric acid secretion
GB9126438D0 (en) *	1991-12-12	1992-02-12	Smithkline Beecham Intercredit	New quinoline derivatives
IS4164A (is) *	1993-06-11	1994-12-12	Ab Astra	Efnasambönd sem hindra flæði magasýru

1994
- 1994-12-08 US US08/351,852 patent/US5556863A/en not_active Expired - Fee Related
1995
- 1995-11-08 AR ARP950100099A patent/AR001996A1/es unknown
- 1995-11-17 PL PL95320754A patent/PL320754A1/xx unknown
- 1995-11-17 NZ NZ297566A patent/NZ297566A/xx unknown
- 1995-11-17 HU HU9800175A patent/HUT77949A/hu unknown
- 1995-11-17 EP EP95941272A patent/EP0796249A1/en not_active Ceased
- 1995-11-17 WO PCT/SE1995/001369 patent/WO1996017830A1/en not_active Ceased
- 1995-11-17 EE EE9700131A patent/EE9700131A/xx unknown
- 1995-11-17 SK SK637-97A patent/SK63797A3/sk unknown
- 1995-11-17 JP JP8517523A patent/JPH10510259A/ja active Pending
- 1995-11-17 MX MX9704136A patent/MX9704136A/es unknown
- 1995-11-17 CN CN95196698A patent/CN1169142A/zh active Pending
- 1995-11-17 CA CA002205896A patent/CA2205896A1/en not_active Abandoned
- 1995-11-17 BR BR9509888A patent/BR9509888A/pt not_active Application Discontinuation
- 1995-11-17 FI FI972410A patent/FI972410A0/fi unknown
- 1995-11-27 ZA ZA9510066A patent/ZA9510066B/xx unknown
- 1995-12-05 TR TR95/01536A patent/TR199501536A2/xx unknown
- 1995-12-07 IL IL11628595A patent/IL116285A0/xx unknown
1997
- 1997-05-22 IS IS4485A patent/IS4485A/is unknown
- 1997-06-03 NO NO972529A patent/NO972529D0/no unknown

Also Published As

Publication number	Publication date
AU697006B2 (en)	1998-09-24
TR199501536A2 (tr)	1996-07-21
MX9704136A (es)	1998-02-28
EE9700131A (et)	1997-12-15
CA2205896A1 (en)	1996-06-13
IL116285A0 (en)	1996-03-31
CN1169142A (zh)	1997-12-31
JPH10510259A (ja)	1998-10-06
PL320754A1 (en)	1997-10-27
AU4274896A (en)	1996-06-26
BR9509888A (pt)	1997-10-21
FI972410L (fi)	1997-06-06
FI972410A7 (fi)	1997-06-06
FI972410A0 (fi)	1997-06-06
EP0796249A1 (en)	1997-09-24
ZA9510066B (en)	1996-06-10
WO1996017830A1 (en)	1996-06-13
US5556863A (en)	1996-09-17
SK63797A3 (en)	1998-07-08
IS4485A (is)	1997-05-22
HUT77949A (hu)	1998-12-28
AR001996A1 (es)	1998-01-07
NO972529D0 (no)	1997-06-03
NZ297566A (en)	1998-12-23

Publication	Publication Date	Title
RU2238271C2 (ru)	2004-10-20	Производные имидазопиридина, способы их получения и промежуточные соединения, фармацевтический препарат на их основе (варианты), способ ингибирования секреции желудочной кислоты, способ лечения желудочно-кишечных воспалительных заболеваний и способ лечения состояний, в которых вовлечено инфицирование h.pylori
JP2001512477A (ja)	2001-08-21	胃酸分泌を阻止するための化合物
US6465505B1 (en)	2002-10-15	Benzyl-substituted benzimidazoles
JP2005501870A (ja)	2005-01-20	治療効果を有する新規なイミダゾピリジン化合物
US7034038B2 (en)	2006-04-25	Enantiomer (-) of tenatoprazole and the therapeutic use thereof
SK197A3 (en)	1997-06-04	Imidazopyridine-azolidinones, preparation method thereof, pharmaceutical composition containing same and their use
NO972529L (no)	1997-06-03	Forbindelse for inhibering av mavesyresekresjon
RU2142454C1 (ru)	1999-12-10	Производные 4-амино-3-ацилхинолина, способ их получения, фармацевтический препарат на их основе, способ получения фармацевтического препарата и промежуточное соединение
AU697006C (en)	1999-05-06	Compounds for inhibition of gastric acid secretion
US7691875B2 (en)	2010-04-06	Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof
MXPA97004136A (en)	1998-02-01	Compounds for inhibition of gastr acid secretion
CZ159597A3 (cs)	1997-10-15	Sloučeniny pro inhibici sekrece žaludeční kyseliny
KR100487029B1 (ko)	2005-11-25	신규화합물
HK1033317B (en)	2006-06-30	Imidazo pyridine derivatives which inhibit gastric acid secretion
HK1088315B (en)	2008-07-25	Novel imidazopyridine compound ii with therapeutic effect